Participation in research

Aim of the study
Acne can change rapidly. Appointments with the dermatologist are only possible every 2-3 months. We are trying to create the conditions to be able to react more quickly in acne therapy in order to achieve better results in the treatment of "acne vulgaris".

"AcneDect" is a software for detecting acne on the face. Through your active cooperation, AcneDect should facilitate communication between you and your doctor and thus the treatment of acne vulgaris. You carry out facial scans yourself, which are used by the software to detect acne. It is being investigated whether the AcneDect software can be trained ("machine learning") to recognize acne skin changes based on the collected scans.

Prerequisites for participation

You suffer from acne vulgaris and are between 10 and 35 years old.

Effort
Duration of participation in the study: 3 months

With the help of a smartphone, which we will lend you, you will photograph your face every day (in the bathroom for constant lighting conditions). In addition, you will fill out a daily questionnaire (approx. 5-10 minutes per day).

4 visits are planned:

Visit 1 (approx. 45 min.): Preliminary examinations and safety clarifications as well as receipt of the smartphone
Visit 2 and 3 (approx. 20 min. each, in weeks 4 and 8): Data transfer
Visit 4 (approx. 20 min., in week 12) data transfer and return of the smartphone

Risks
No health risks are to be expected.

Benefits
This study can provide important information for the treatment and therapy of acne vulgaris. With the help of acne detection software, it may be possible to control the treatment of your acne better and more efficiently. It is expected that patients suffering from the disease will benefit from this technology in the future. It is possible that you will not derive any personal benefit from participating in the study.

Contact us
Study management

Prof. Dr. med. Dr. sc. nat. A. Navarini
Chief Physician Dermatology & Allergology, University Hospital Basel

Are you interested in participating in this study?

Patients of legal age should contact:
Outpatient Study Center USB, University Hospital Basel
Vanessa Grassedonio
Phone +41 61 328 55 41, asz@usb.ch

Underage patients should contact:
Outpatient Study Center UKBB, University Children's Hospital Basel
Tel. +41 61 704 28 53, asz@ukbb.ch

Please note that your data will be registered if you are contacted by telephone or in writing. If you are not interested in participating in the study, your data will be deleted immediately.

Aim of the study
The AlP-FrUiT study investigates preventive bladder irrigation with hyaluronic acid and chondroitin sulphuric acid (= prophylaxis) compared to bladder irrigation without active ingredients (= placebo) for recurrent urinary tract infections in women. This non-antibiotic prophylaxis has already proven its efficacy in several studies.

The aim of our study is to investigate the extent to which these bladder irrigations reduce the rate of urinary tract infections. In addition, the aim is to reduce the use of antibiotics - for the treatment and prophylaxis of urinary tract infections - to a necessary minimum without jeopardizing patient safety.

Prerequisites for participation

• Recurrent urinary tract infections
• 18-75 years of age
• No long-term use of antibiotics or other prophylactic measures against urinary tract infections
• No previous urogenital diseases (residual urine, urethral strictures, urethral diverticula, urinary stones, reflux, tumors or foreign bodies in the urinary system, prolapse)
• No disease of the immune system (such as diabetes mellitus or renal insufficiency)
• No pregnancy, spermicides, IUD
• No mental illness

Effort

The study involves 7 bladder irrigations over a period of 3 months. A further 9 months serve as a follow-up: a single visit is planned 12 months after the start of the study. In the meantime, we offer you an app on your cell phone or tablet to record any symptoms caused by the bladder irrigation, bladder inflammation or discomfort when urinating. Short questionnaires are made available here at regular intervals for you to answer, which will also help you to classify your symptoms. The time required for each instillation is 15 minutes. In total, 360 minutes are expected over the course of a year.

Risks
No health risks are to be expected.

Benefits
All data will be treated confidentially. The study procedure and the study medication are free of charge for the participants.

The app offers you an opportunity to assess your symptoms and whether a visit to the doctor is recommended or can be avoided. You can also communicate directly with the study team.

You can make a contribution to science and avoid the unnecessary use of antibiotics.

Contact us
Are you interested? Get in touch with:

Dr. Kathrin Bausch
kathrin.bausch@usb.ch

Please note that your data will be registered if you contact us by telephone or in writing. If you are not interested in participating in the study, your data will be deleted immediately.

Study management
Prof. Dr. Dr. med. Alexander Navarini
Dermatology Polyclinic, University Hospital Basel

Aim of the study
The drug Otezla® is being investigated as a new therapeutic approach for the treatment of moderate to severe psoriasis of the scalp. The drug is already approved for the treatment of psoriasis all over the body and has a demonstrable effect on the skin. The aim is to investigate whether Otzela® can also reduce itching and improve quality of life in head psoriasis.

Prerequisites for participation
You suffer from moderate to severe psoriasis of the scalp (20% of the scalp affected)
You are not pregnant or breastfeeding

Effort required
The study lasts 52 weeks. The patients are randomly divided into two groups. One group receives Otezla® from the beginning. The other group is given a placebo for the first 16 weeks of treatment. Thereafter, these patients will also be treated with Otzela® for the remainder of the study.

7 visits are planned:

Visit 1 (2 h): Preliminary examinations and safety clarifications
Visit 2 (2 h): Confirmation of study inclusion, scalp photography, physical examination, questionnaire
Visit 3-6 (1 h each, weeks 4, 16, 32, 52): physical examination, scalp photography
Visit 7: telephone call (15 min.)

Benefits
This study can provide important information about the treatment of psoriasis of the scalp with Otezla®. Your scalp psoriasis may improve as a result of treatment with the drug. However, you may also not benefit from it. In the phase of treatment with the placebo, you will not derive any benefit.

Study director
Prof. Dr. Dr. med. Alexander Navarini
Dermatology Polyclinic, University Hospital Basel

Contact Us
Are you interested in participating in this study?

For further information please contact:
Dermatologic Polyclinic
Phone +41 61 265 40 99
aprescalp@usb.ch

Please note that your data will be registered if you are contacted by telephone or in writing. If you are not interested in participating in a study, your data will be deleted immediately.

Study director and investigator
Dr. med. Thilo Burkard
University Hospital Basel
thilo.burkard@usb.ch
+41 61 265 25 25

Aim of the study

Our study aims to find out whether the use of a new cell phone app can support patients in taking their medication optimally and thus also in achieving optimal treatment results.

Prerequisites for participation

You are over 18 years old, own a smartphone, suffer from high blood pressure and have to take more than 4 tablets per day.

If you are interested, we can advise you individually as to whether participation in our study is possible.

Costs

For 2 x 3 months, support from a digital companion in the form of an app or further support with standard treatment.

1 visit at the beginning and 4 visits over the study period of 6 months. The visits are carried out with our study team at the University Hospital Basel.

Time required: Each visit takes approximately 1-2 hours.
During the visits, your blood pressure will primarily be measured and you will complete questionnaires about the app and your medication intake. In addition, 24-hour blood pressure monitoring will be carried out at 3 points in time.

Expense allowance of CHF 100 at the end of the study and reimbursement of travel expenses.

Benefit

Collabree: An intervention to improve the regularity of medication intake

A new digital companion

Regular and optimal medication intake leads to better treatment outcomes and can reduce treatment costs.

Contact us

Would you like more information and would you like to participate? Please contact our study doctor

Runi Erbil
University Hospital Basel

runi.erbil@usb.ch

+41 61 328 43 17

Please note that your data will be registered when you contact us. This data will be treated confidentially and deleted if you do not participate.

Investigator: Prof. Mirjam Christ-Crain, Department of Endocrinology, University Hospital Basel

Test subjects wanted for scientific study:

We are looking for healthy, normal-weight (BMI 18-29kg/m2) individuals between the ages of 18 and 65 for a scientific physiological study. Women must be taking the pill.

Aim of the study:

The aim of this study is to investigate the influence of the test substance Apelin on urine excretion and blood sodium levels after these have been artificially lowered.

Apelin is an endogenous hormone that promotes water excretion via the kidneys. This effect could open up new perspectives for the treatment of people with low blood sodium levels due to illness.

Course of the study:

The study will take place on four dates at the Outpatient Study Center of the University Hospital Basel. There will first be a one-hour preliminary examination, followed by three full-day study visits. There must be at least 14 days between the study visits.

Each participant takes part in the three study visits, during which the sodium level in the blood is first artificially lowered with medication and increased fluid administration. You will then receive either an infusion without a test substance (= placebo), an infusion with a low dosage of Apelin or an infusion with a higher dosage of Apelin. At each study visit, you will receive one of the three possible infusions, and neither you nor the investigator will know which infusion it is.

During the study visits, your blood and urine values, blood pressure, pulse and weight will be checked every hour. In addition, you will be asked about any pre-existing conditions and any symptoms that may occur (e.g. headaches, nausea).

Expense allowance (incl. travel expenses): CHF 900.

All data collected will be treated confidentially. There is no medical benefit for the test subjects.

If you are interested in participating in a study and the above criteria apply to you, or if you would like further information, please contact:

Sven Lustenberger

Department of Endocrinology, University Hospital Basel

Petersgraben 4

4031 Basel

E-Mail: sven.lustenberger@usb.ch

Phone: 061 328 62 64

Please note that your data will be registered if you contact us by telephone. If you are not interested in participating in the study, your data will be deleted immediately.

In our study, we are investigating the role of the stress hormone cortisol during fasting, for which the test subjects have to fast for 2 x 2 days. We suspect that the natural increase in cortisol during fasting has an influence on appetite perception. During one fasting period, the increase in cortisol in the body is suppressed with medication, while during the other fasting period the test subjects receive placebo medication.

The aim of the study is to gain a more precise understanding of the development of appetite. A better understanding of the development of appetite can then lead to new therapeutic approaches for obesity.

We are looking for: healthy male volunteers aged 18 - 40 years with a BMI between 18.0 and 27.0.

Contact

Med. pract. Freschteh Moradi
+41 61 328 55 23
freschteh.moradi@usb.ch

Link:https://clinicaltrials.gov/study/NCT05919992?term=gluco-starve&distance=50&rank=1

Aim of the study

The University Hospital Basel is conducting a study in collaboration with the University Hospital Zurich to investigate the efficacy of LSD in patients with life-threatening illnesses and limited life expectancy in the palliative setting with regard to anxiety, depression and pain.

Conditions for participation

For this study, we are looking for patients aged at least 25 with a life-threatening illness and limited life expectancy.

Wall

You will be blinded and randomized to receive either 2 low doses of LSD (0.025 mg "microdose") or 2 medium to high doses of LSD (0.1 or 0.2 mg) 2 weeks apart.

Duration

The study lasts a total of 12 weeks.
During this time:
- Initial examination (interview, blood sample, urine sample, physical examination): 1 appointment of 2 hours each
- Study visits before study days (interviews, questionnaires, preparation for study days): 2 appointments of 0.5-1 hour each
- Study days (low or higher dose of LSD): 2 appointments of 12 hours each
- Study visits after/between the study days (interviews, questionnaires, follow-up of the study days): 6 appointments of 0.5-1 hour each
- Study visits after both study days (interviews, questionnaires): 3 appointments of 1 hour each
- Final examination (interview, blood sample, physical examination): 1 appointment of 2 hours each

Location

University Hospital Basel (USB) or University Hospital Zurich (USZ).

Compensation/costs

You will not receive any compensation. There are no costs for you (except for travel).

Contact us

If you are interested, please contact Dr. med. Yasmin Schmid (University Hospital Basel), tel. +41 61 328 68 47, e-mail: yasmin.schmid@usb.ch

or Prof. Dr. med. David Blum (University Hospital Zurich), tel. +44 255 37 42, e-mail: david.blum@usz.ch.

Please note that your data will be registered if you contact Dr. Schmid and Prof. Blum by telephone. If you are not interested in participating in the study, your data will be deleted immediately.

Study management
Prof. Dr. med. Marc Donath
Endocrinology, Diabetology & Metabolism
University Hospital Basel

Aim of the study

To investigate the safety and efficacy of dapansutril capsules in patients with moderate COVID-19 symptoms. The study tests whether taking dapansutril can reduce COVID-19 inflammation to prevent a worse course.

Prerequisite for participation

If you have tested positive for COVID-19, have a fever and meet at least 1 of the following criteria, you could take part in the study:

• 70 years or older
• Overweight (BMI ≥ 30 kg/m2)
• diabetes
• High blood pressure
• Respiratory disease
• Heart failure
• Coronary artery disease

Someone from the study team will contact you by phone to ask if you would like to take part in the study. If we already have data about you at the hospital and see that you do not meet the eligibility criteria, we will not call you.

Effort

The study will be conducted with two groups of patients. You will be randomly assigned to a control group (receiving placebo) or an intervention group (receiving investigational drug dapansutril).

Duration: 45 days

• Day 1-14: Intake of placebo/dapansutril and entry in the patient diary
• Day 1, 4, 8 and 15: visits of approx. 2 hours each at your home with questioning and
• blood sampling
• Day 29 and 45: Telemedical visits

Risks

Undesirable side effects of dapansutril are possible. The most frequently reported (but less than 10%) were

• Diarrhea
• joint pain
• headache

Benefit

This study may provide important information about the treatment of moderate COVID-19 symptoms with dapansutril. Your symptoms caused by COVID-19 disease may be alleviated with the investigational product.

However, you may not benefit from it.

We are investigating whether acute olfactory therapy with two different fragrances influences food selection and calorie intake at the test buffet in people with obesity. We also want to find out what influence the fragrances have on metabolic parameters. The overall aim of our study is to find out whether scent exposure could represent a possible new therapeutic option for people with overweight and obesity.

Participation requirements: We are looking for people who are overweight (BMI ≥ 30 ^kg/m2) aged 18-60 years.

Link: https://kofam.ch/de/studienportal/nach-klinischen-versuchen-suchen/188640/studie/63647

Contact:

Lisa Hurni

lisamaria.hurni@usb.ch

+41 61 328 48 45

As part of a clinical study, we are comparing the effect of a psychedelic substance compared to placebo in patients with cluster headaches. All patients receive the psychoactive substance three times and placebo three times, but in a different and randomly selected order. A total of 10 appointments (6 study days, 1 entry examination, 1 exit examination, 2 appointments without study medication) will take place at the University Hospital Basel. Over a total of 46 weeks, the course of the cluster headaches will be recorded with the help of a standardized headache diary.

Who

People aged at least 25 with cluster headaches

Effort required

Study duration per patient: 46 weeks
Entry examination: 1 x 2 hours
Study visits (3 x substance / 3 x placebo): 6 times 10 hours
Study visits (without substance administration, questionnaire): 2 times 1 hour
Exit examination: 1 time 1 hour

Location

University Hospital Basel

Compensation/costs

You will not incur any costs for the study (except possibly travel expenses), no compensation

Benefits

Based on reports, it is possible that the psychedelic substance reduces the cluster headaches and improves your well-being. However, it is unclear whether you as the test subject will derive any direct benefit. The study will help to scientifically assess the effectiveness of the substance and thus generate a potential benefit for other patients.

Contact

If you are interested, please contact Prof. Dr. med. Matthias Liechti, Deputy Head of Clinical Pharmacology and Toxicology, University Hospital Basel, 061 328 68 68, matthias.liechti@usb.ch

All information will be treated confidentially.

The LYMPH trial, led by Prof. Elisabeth A. Kappos, aims to improve the quality of life of patients with breast cancer-associated lymphoedema (BCRL).

At the University Hospital Basel and at numerous locations worldwide, the study compares surgical with non-surgical treatment of BCRL in order to gain scientifically sound findings on the effectiveness of microsurgical operations in combination with conservative therapy.

Participation is open to

• People over the age of 18 who have completed or are undergoing breast cancer treatment,
• suffer from chronic breast cancer-related lymphoedema,
• have not yet had surgery to treat lymphoedema.

Further information on lymphoedema and the LYMPH trial can be found at www.lymphtrial.com

Take part in a study for the treatment of COVID-19

The OPTICOV study aims to test whether drug treatment can improve COVID-19 symptoms (in the short and long term) in immunocompromised people.

Conditions for participation

• 16 years old or older
• Weight > 40 kg
• Asymptomatic or with mild to moderate symptoms
• SARS-CoV-2 test positive
• Immunocompromised*

Procedure of the study

• 3 capsules morning and evening for 5 to 10 days, with some participants receiving an intravenous infusion on the first day.
• 6 visits to the doctor, 2 telephone calls over 3 months
• Completion of a questionnaire over 21 days and then after 1 to 3 months

Information and contact

annika.bargetzi@usb.ch

andrea.erba@usb.ch

nina.khanna@usb.ch

Phone +41 61 265 25 25

To the flyer

*e.g. due to a significant immunodeficiency, neutropenia, lymphopenia, leukemia, transplantation